Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Rationale for using nabumetone and clinical experience].

S H Roth1

  • 1Centre de Recherche et d'Education de l'Arizona, Phoenix 85012, Etats-Unis.

Drugs
|June 7, 2000
PubMed
Summary

Nabumetone, a nonsteroidal anti-inflammatory drug (NSAID), offers excellent long-term tolerability and efficacy for arthritis due to its unique pharmacokinetic profile. Its cost-effectiveness and once-daily dosing make it a suitable choice for chronic inflammatory conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Whose pain is it anyhow?

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2008
Same author

Finessing fibromyalgia.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2006
Same author

Anoxic depolarization of rat hippocampal slices is prevented by thiopental but not by propofol or isoflurane.

British journal of anaesthesia·2005
Same author

Small-dose pentobarbital enhances synaptic transmission in rat hippocampus.

Anesthesia and analgesia·2001
Same author

Arthritis therapy: a better time, a better day.

Rheumatology (Oxford, England)·2001
Same author

Effects of repeated hydrogen sulphide (H2S) exposure on learning and memory in the adult rat.

Neurotoxicology·2001

Area of Science:

  • Pharmacology
  • Rheumatology
  • Drug Development

Background:

  • Nabumetone is a widely used nonsteroidal anti-inflammatory drug (NSAID) with over a decade of clinical application.
  • Its popularity stems from a unique pharmacokinetic profile and favorable pharmacodynamic safety features.
  • Nabumetone is a nonacidic prodrug metabolized to 6-methoxy-2-naphthylacetic acid (6-MNA), exhibiting COX-2 preferential activity and lacking enterohepatic recirculation.

Purpose of the Study:

  • To review the clinical experience and therapeutic advantages of nabumetone.
  • To highlight its unique pharmacokinetic and safety features contributing to long-term tolerability.
  • To compare nabumetone's profile with newer selective COX-2 inhibitors in terms of efficacy, tolerability, and cost-effectiveness.

Main Methods:

  • Review of clinical experience and published data on nabumetone.
  • Analysis of pharmacokinetic and pharmacodynamic properties.
  • Comparative assessment with selective COX-2 inhibitors regarding tolerability and cost.

Main Results:

  • Nabumetone demonstrates excellent long-term tolerability in osteoarthritis and rheumatoid arthritis populations.
  • Its 24-hour half-life allows for convenient once-daily dosing, suitable for chronic anti-inflammatory therapy.
  • Nabumetone exhibits clear cost-effectiveness advantages compared to potentially more expensive selective COX-2 NSAIDs.

Conclusions:

  • Nabumetone's established tolerability profile, efficacy, and cost-effectiveness make it a valuable option for long-term arthritis management.
  • Its unique prodrug characteristics and COX-2 preferential activity contribute to its favorable safety and tolerability.
  • Nabumetone remains a reliable and accessible choice for anti-inflammatory therapy while newer agents accrue long-term data.

Related Experiment Videos